Between January and August 2020, there has been approximately 48.2 thousand deaths in England and Wales with COVID-19 as an underlying cause. As illustrated in the table, the number of deaths as a result of COVID-19 are much higher than from either pneumonia or influenza. There has been over three times the number of deaths from COVID-19 than pneumonia and influenza so far in 2020. The overall number of confirmed COVID-19 cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

In 2020, approximately ** men and ** women per 100,000 population died as a result of pneumonia in England and Wales. In every year in the provided time interval the mortality rate was higher among men, although both genders have experienced a general decline in deaths from pneumonia. Regionally, the North West had the highest mortality rate for both genders.

Pneumonia risk groups

The age groups most at risk from pneumonia is undoubtedly the older age groups. In 2021, in England and Wales, pneumonia was the cause of death for approximately *** thousand over ** year olds, of which *** thousand were women. Furthermore, around *** thousand individuals aged between 80 and 89 years lost their lives due to pneumonia in 2021.

Prevalence of other lung diseases

In England and Wales in 2019, the mortality rate from bronchitis for men was around ** per 100,000 population, while the rate for women was approximately **. The mortality rate for bronchitis was higher than pneumonia, this is caused in part by the large decline in the mortality rate of pneumonia since the year 2000.

Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.

Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.

This statistic shows the deaths with influenza as an underlying cause in England and Wales in 2023, by age and gender. In this year, influenza was the underlying cause of *** deaths for women aged 90 years and over. Respiratory disease burden in the UK As of 2023, tuberculosis cases had also been on the rise, with ***** new cases and relapses reported in 2023. The ***** age group was most affected by this respiratory disease, accounting for approximately ***** cases. Pneumonia, another serious respiratory condition, caused over ***** deaths among women aged 90 and older in the same year, with a further ***** men in the same age group having pneumonia as their underlying cause of death. Vaccination prevalence and accessibility In the years 2014-2015, **** percent of individuals aged 65 and over in the North West of England were immunized against influenza. This was the region with the highest share of elderly vaccinated against influenza, while this figure was the lowest in London, around **** percent. Community pharmacies have played a crucial role in providing seasonal influenza vaccination services – as of 2023/24, ** percent of community pharmacies in the South of England offered influenza vaccination advanced service, while in London, the figure reached ** percent.

BackgroundIn October 2017, the United Kingdom Joint Committee on Vaccination and Immunisation (JCVI) recommended removal of one primary dose of the 13-valent pneumococcal conjugate vaccine (PCV13) from the existing 2+1 schedule (2, 4, 12 months). We conducted a mathematical modelling study to investigate the potential impact of a 1+1 (3, 12 month) schedule on invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP). Our results and those from a 1+1 immunogenicity study formed the key evidence reviewed by JCVI.Methods and findingsWe developed age-structured, dynamic, deterministic models of pneumococcal transmission in England and Wales to describe the impact on IPD of 7-valent PCV (PCV7; introduced in 2006) and PCV13 (introduced in 2010). Key transmission and vaccine parameters were estimated by fitting to carriage data from 2001/2002 and post-PCV IPD data to 2015, using vaccine coverage, mixing patterns between ages, and population data. We considered various models to investigate potential reasons for the rapid increase in non-PCV13 (non-vaccine serotype [NVT]) IPD cases since 2014. After searching a large parameter space, 500 parameter sets were identified with a likelihood statistically close to the maximum and these used to predict future cases (median, prediction range from 500 parameter sets). Our findings indicated that the emergence of individual NVTs with higher virulence resulting from ongoing replacement was likely responsible; the NVT increase was predicted to plateau from 2020. Long-term simulation results suggest that changing to a 1+1 schedule would have little overall impact, as the small increase in vaccine-type IPD would be offset by a reduction in NVT IPD. Our results were robust to changes in vaccine assumptions in a sensitivity analysis. Under the base case scenario, a change to a 1+1 schedule in 2018 was predicted to produce 31 (6, 76) additional IPD cases over five years and 83 (−10, 242) additional pneumococcal-CAP cases, with together 8 (−2, 24) additional deaths, none in children under 15 years. Long-term continuation with the 2+1 schedule, or changing to a 1+1, was predicted to sustain current reductions in IPD cases in under-64-year-olds, but cases in 65+-year-olds would continue to increase because of the effects of an aging population. Limitations of our model include difficulty in fitting to past trends in NVT IPD in some age groups and inherent uncertainty about future NVT behaviour, sparse data for defining the mixing matrix in 65+-year-olds, and the methodological challenge of defining uncertainty on predictions.ConclusionsOur findings suggest that, with the current mature status of the PCV programme in England and Wales, removing one primary dose in the first year of life would have little impact on IPD or pneumococcal CAP cases or associated deaths at any age. A reduction in the number of priming doses would improve programmatic efficiency and facilitate the introduction of new vaccines by reducing the number of coadministered vaccines given at 2 and 4 months of age in the current UK schedule. Our findings should not be applied to other settings with different pneumococcal epidemiology or with immature programmes and poor herd immunity.

Adjusted odds ratios with 95% confidence interval from multivariable logistic regression model with GEE for the outcome COVID-19 mortality.

Summary of demographics, COVID-19 status, and comorbidity variables of all COVID-19 patients from January 29, 2020–August 16, 2021 in Mexico.